Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NovoPen 4, NovoPen 3 · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| NovoPen™ 4 | DEVICE | - |
| NovoPen® 3 | DEVICE | - |
Inclusion Criteria: * Type 1 or type 2 diabetes mellitus for at least 12 months * Adults at least 18 years * Children/adolescents between 9-18 years * HbA1c lesser than or equal to 11.0% Exclusion Criteria: * Known or suspected alcohol or drug abuse * Patients who are not able to read the user ma...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
NovoPen 4 is an insulin delivery pen system used in patients with diabetes, including type 1 and type 2 diabetes. It is designed to administer insulin and was studied in a Phase 3 clinical trial comparing two pen systems in patients treated with insulin.
NovoPen 4 is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company conducted a Phase 3 clinical trial to evaluate the pen system in patients with diabetes.
NovoPen 4 is in Phase 3 clinical development. A Phase 3 trial, NCT00569998, has been completed, evaluating the pen system in patients with diabetes. The trial enrolled 208 participants across multiple European countries.
NovoPen 4 was studied in a completed Phase 3 clinical trial with the identifier NCT00569998. The trial, titled 'Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin,' enrolled 208 patients with type 1 or type 2 diabetes in Austria, Germany, Italy, Netherlands, and the United Kingdom.
NovoPen 4 and NovoPen 3 are both insulin delivery pen systems developed by Novo Nordisk. They were compared in a clinical trial (NCT00569998) to evaluate their use in patients with diabetes, but they are distinct products.